Amyris, Inc. (AMRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

15.36-0.18 (-1.16%)

At close: 4:00PM EDT

15.47 +0.11 (0.72%)
After hours: 5:55PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	15.54
Open	15.32
Bid	15.40 x 800
Ask	15.45 x 1100
Day's Range	15.05 - 15.82
52 Week Range	1.88 - 23.42
Volume	3,905,827
Avg. Volume	5,142,250

Market Cap	4.197B
Beta (5Y Monthly)	1.23
PE Ratio (TTM)	N/A
EPS (TTM)	-1.88
Earnings Date	May 06, 2021 - May 10, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	26.60

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

PR Newswire
Amyris Announces Pricing of a $300.0 Million Public Offering (Secondary and Primary) of Common Stock
Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the pricing of an underwritten public offering of an aggregate of 19,047,619 shares of its common stock at a public offering price of $15.75 per share, which consists of a secondary offering of 11,390,797 shares to be sold, in the aggregate, by DSM International B.V. and affiliates of Vivo Capital LLC (the selling stockholders) and 7,656,822 shares to be sold by Amyris.
- Fusion Acquisition Corp. II Announces the Separate Trading of its Common Stock and Warrants, Commencing April 19, 2021
  GlobeNewswire
- Identiv Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock and Closing of Public Offering
  GlobeNewswire
PR Newswire
Amyris Announces Proposed Public Offering (Secondary And Primary) Of Common Stock
Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the commencement of a proposed underwritten public offering of shares of its common stock.
- KnowBe4 Announces Launch of Initial Public Offering
  PR Newswire
- DoubleVerify Announces Launch of Initial Public Offering
  GlobeNewswire
PR Newswire
Amyris Brand Biossance® partners With Reese Witherspoon To Accelerate Clean Beauty Movement
Amyris, Inc., (Nasdaq: AMRS) a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced a 5-year partnership with Reese Witherspoon as global brand ambassador for Biossance®, one of the fastest growing clean and sustainable skincare brands in the world.